Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy

摘要

Background: In our recent clinical trial, the addition of omalizumab to oral immunotherapy (OIT) for milk allergy improved safety, but no significant clinical benefit was detected.